Skip to main content

Table 2 Comparison of the EGFR and KRAS mutation status in the tumor tissue and plasma

From: PNA clamping-assisted fluorescence melting curve analysis for detecting EGFR and KRAS mutations in the circulating tumor DNA of patients with advanced non-small cell lung cancer

Plasma EGFR mutation status
 Tissue EGFR mutation status Positive Negative Total
  Positive 34 17 51
  Negative 18 125 143
  Total 52 142 194
  G719A 19DEL L858R T790M Exon20ins S768I Multiple Wild Total
 G719A          0
 19DEL   21 1 1    1 14 38
 L858R    9    1   3 13
 T790M          0
 exon20ins          0
 S768I          0
 Multiple          0
 Wild type   3 3 7 2   3 125 143
 Total 0 24 13 8 2 1 4 142 194
  N % (95 % CI)
 Concordance 159 82.0 (76.5–87.4)
 Sensitivity 34 66.7 (60.0–73.3)
 Specificity 125 87.4 (82.7–92.1)
 PPV 52 65.4 (58.7–72.1)
 NPV 142 88.0 (83.5–92.6)
Plasma KRAS mutation status
 Tissue KRAS mutation status Positive Negative Total
  Positive 6 6 12
  Negative 13 110 123
  Total 19 116 135
  Codon 12 Codon 13 Codon 59 Codon 61 Codon 12/61 Wild Total
 Codon 12 3      5 8
 Codon 13   1     1 2
 Codon 59        
 Codon 61    1 1    2
 Codon 12/61        
 Wild type 10    2 1 110 123
 Total 13 1 1 3 1 116 135
  N % (95 % CI)
 Concordance 116 85.9 (80.1–91.8)
 Sensitivity 6 50.0 (41.6–58.4)
 Specificity 110 89.4 (84.2–94.6)
 PPV 19 31.6 (23.7–39.4)
 NPV 116 94.8 (91.1–98.6)